PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification
Clinical and Translational Medicine · 2024-10 · 14 (10)
DOI: 10.1002/ctm2.70045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 18.10.2024. Verfasst von Haoyu Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Rare Metabolic Disease, Department of Biochemistry and Molecular Biology, The Key Laboratory of Human Functional Genomics of Ji…. Hauptthemen laut MEDLINE: Liver Neoplasms, Pyrroline Carboxylate Reductases, delta-1-Pyrroline-5-Carboxylate Reductase, Insulin Receptor Substrate Proteins. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Innovation Team Program Foundation.
Abstract (Originalsprache)
Background
Liver cancer (LC) is among the deadliest cancers worldwide, with existing treatments showing limited efficacy. This study aimed to elucidate the role and underlying mechanisms of pyrroline‐5‐carboxylate reductase 1 (PYCR1) as a potential therapeutic target in LC.
Methods
Immunohistochemistry and Western blot were used to analyse the expression of PYCR1 in LC cells and tissues. EdU assays, colony‐forming assays, scratch wound healing assays, Transwell assays, nude mouse xenograft models and nude mouse lung metastasis models were used to detect the growth and metastasis abilities of LC cells. Transcriptome sequencing was used to search for downstream target genes regulated by PYCR1, and metabolomics was used to identify the downstream metabolites regulated by PYCR1. ChIP assays were used to analyse the enrichment of H3K18 lactylation in the IRS1 promoter region.
Results
We found that the expression of PYCR1 was significantly increased in HCC and that this high expression was associated with poor prognosis in HCC patients. Knockout or inhibition of PYCR1 inhibited HCC cell proliferation, migration and invasion both in vivo and in vitro. In addition, we revealed that knocking out or inhibiting PYCR1 could inhibit glycolysis in HCC cells and reduce H3K18 lactylation of the IRS1 histone, thereby inhibiting IRS1 expression.
Conclusions
Our findings identify PYCR1 as a pivotal regulator of LC progression that influences tumour cell metabolism and gene expression. By demonstrating the potential of targeting PYCR1 to inhibit LC cell proliferation and metastasis, this study identified PYCR1 as a promising therapeutic target for LC. Highlights Pyrroline‐5‐carboxylate reductase 1 (PYCR1) promotes the proliferation and metastasis of liver cancer (LC) cells. The expression of PYCR1 in LC is regulated by DNA methylation. Knocking down or inhibiting PYCR1 inhibits glycolysis as well as the PI3K/AKT/mTOR and MAPK/ERK pathways in LC cells. PYCR1 regulates the transcriptional activity of IRS1 by affecting H3K18 lactylation in its promoter region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Rare Metabolic Disease, Department of Biochemistry and Molecular Biology, The Key Laboratory of Human Functional Genomics of Jiangsu Province, Key Laboratory of Targeted Intervention of Cardiovascu…
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
- School of Basic Medicine and Clinical Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, China.
- Department of Endocrinology, The First affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Endocrinology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Huaian, Jiangsu, China.
- Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: John Zhong Li
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Innovation Team Program Foundation
Zitieren
APA
Wang, H., Xu, M., Zhang, T., Pan, J., Li, C., Pan, B., Zhou, L., Huang, Y., Gao, C., He, M., Xue, Y., Ji, X., Zhang, X., Wang, N., Zhou, H., Wang, Q., & Li, J. Z. (2024). PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification. Clinical and Translational Medicine, 14(10). https://doi.org/10.1002/ctm2.70045
Vancouver
Wang H, Xu M, Zhang T, Pan J, Li C, Pan B, et al. PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification. Clinical and Translational Medicine. 2024;14(10). doi:10.1002/ctm2.70045
BibTeX
@article{Wang2024,
author = {Wang, Haoyu and Xu, Mu and Zhang, Tong and Pan, Jinkun and Li, Chaopu and Pan, Bei and Zhou, Linpeng and Huang, Yun and Gao, Chenzi and He, Mengping and Xue, Yao and Ji, Xuetao and Zhang, Xu and Wang, Ning and Zhou, Hongwen and Wang, Qian and Li, John Zhong},
title = {PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {10},
doi = {10.1002/ctm2.70045}
}
EUVIMED